Core Viewpoint - A class action lawsuit has been filed against Altimmune Inc. by Berger Montague PC on behalf of investors who acquired Altimmune securities between August 10, 2023, and June 25, 2025, following disappointing trial results for its drug Pemvidutide [1][2][3]. Company Overview - Altimmune Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [2]. Legal Action Details - The lawsuit is based on a press release issued by Altimmune on June 26, 2025, which announced that the IMPACT Phase 2b trial of Pemvidutide failed to achieve statistical significance in its primary endpoint related to fibrosis reduction, attributed to a higher-than-expected placebo response [3]. - Following the announcement, Altimmune's stock price plummeted by 53.2%, dropping from a close of $7.71 on June 25, 2025, to $3.61 on June 26, 2025 [4]. Investor Information - Investors who purchased Altimmune securities during the class period have until October 6, 2025, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the lead plaintiff deadline of October 6, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Altimmune securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 6, 2025 [2]. - The lawsuit alleges that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit due to disappointing results from its Phase 2b MASH trial of Pemvidutide, which led to a significant drop in its stock price [1][3]. Group 1: Class Action Details - The Portnoy Law Firm is advising Altimmune investors to join a class action for those who purchased securities between August 10, 2023, and June 25, 2025 [1]. - Investors have until October 6, 2025, to file a lead plaintiff motion [1]. Group 2: Trial Results and Stock Impact - On June 26, 2025, Altimmune announced that its Phase 2b MASH trial did not achieve statistical significance in the primary endpoint of fibrosis reduction, despite showing a positive trend [3]. - The stock price of Altimmune fell by $4.10, or 53.2%, closing at $3.61 per share following the announcement of the trial results [3]. Group 3: Legal Representation - The Portnoy Law Firm specializes in representing investors in claims related to corporate wrongdoing and has recovered over $5.5 billion for investors in the past [4].

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune - **Product**: GLP-1/glucagon dual agonist for MASH (Metabolic Associated Steatotic Liver Disease) and weight loss Key Points Product Development and Efficacy - Altimmune is developing a GLP-1/glucagon dual agonist that targets liver effects and metabolic benefits, showing promising results in a 24-week Phase 2 trial with class-leading MASH resolution and significant weight loss of approximately 6% at 24 weeks [2][3][20] - The drug demonstrated excellent tolerability without dose titration, which is crucial for patient adherence [3][12] - The treatment shows rapid effects on liver health and weight loss, with expectations of continued improvement as treatment progresses [20][23] Regulatory Considerations - The company is preparing for potential FDA approval based on MASH resolution endpoints, with a focus on both traditional biopsy-based and non-invasive tests (NITs) [11][25] - AI-enabled histological assessments for fibrosis are being considered, with positive feedback expected from the FDA in Q4 [8][9][25] - Altimmune plans to incorporate flexibility in trial design to adapt to regulatory changes, potentially moving away from biopsy requirements [25][26] Market Positioning and Competitive Landscape - The recent interest from large pharmaceutical companies in MASH treatments indicates a growing market, with Altimmune positioned to leverage its dual-action therapy [28][30] - The company believes that its single-molecule approach, which combines liver-targeting and metabolic effects, offers a competitive advantage over combination therapies that require multiple drugs [29][34] - Altimmune aims to treat a broad spectrum of patients (F1 to F4) with its drug, addressing both early and late-stage MASH patients [32][33] Financial and Strategic Outlook - Altimmune is focused on improving its balance sheet to fund the Phase 3 trial and is exploring various funding options [39] - The company holds Fast Track status for alcohol use disorder (AUD) and is optimistic about its ongoing trials in this area, with expected readouts in 2026 [36][38] Additional Insights - The company emphasizes the importance of early efficacy in treatment to maintain patient adherence, which is critical given the high discontinuation rates seen with other GLP-1 therapies [16][17] - Altimmune's strategy is to prioritize high-value treatments for complex diseases rather than competing directly in the obesity market, positioning itself as a multifaceted solution provider [38] This summary encapsulates the key insights from the Altimmune conference call, highlighting the company's innovative approach to treating MASH and its strategic positioning in the market.

LOS ANGELES--(BUSINESS WIRE)--Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT. ...

PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) --  Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the “Class Period”). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class ...

Core Insights - Altimmune, Inc. has appointed Dr. Christophe Arbet-Engels as Chief Medical Officer to lead the Phase 3 development of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - Dr. Arbet-Engels brings over 30 years of experience in clinical development, regulatory approvals, and commercial launches, which will be crucial for advancing pemvidutide [2] - The company aims to establish a new standard of care in treating hepato-metabolic disorders, with upcoming data from the IMPACT trial and ongoing Phase 2 trials in Alcohol Use Disorder and Alcohol-associated Liver Disease [2] Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [6] - The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder, Alcohol-associated Liver Disease, and obesity [6] Leadership Transition - Dr. Scott Harris, the previous Chief Medical Officer, will retire but remain as a Senior Strategic Advisor until February 2026 [1][2] - Dr. Arbet-Engels has previously held senior roles at X4 Pharmaceuticals, Neurogastrx, Millendo Therapeutics, and Poxel Pharmaceuticals, contributing to successful regulatory processes and clinical programs [2] Inducement Grant Details - Dr. Arbet-Engels will receive options to purchase 450,000 shares and 150,000 restricted stock units (RSUs) as part of his compensation package [3][4] - The options will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date [4][5] - The RSUs will also vest over four years, with one-fourth vesting on the one-year anniversary and the remainder in three equal installments [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors must move the Court by October 6, 2025, to serve as lead plaintiff, representing other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Background - The lawsuit alleges that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4] - Altimmune is accused of inflating expectations for positive results while concealing adverse data from the placebo group, leading to investor damages when the true results were revealed [4]

Core Viewpoint - Berger Montague PC is investigating claims against Altimmune, Inc. following a class action lawsuit related to the company's performance and disclosures regarding its clinical trials [1][3]. Group 1: Company Overview - Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [1]. Group 2: Legal Actions - A class action lawsuit has been filed against Altimmune, with investors who purchased securities between August 10, 2023, and June 25, 2025, having until October 6, 2025, to seek appointment as lead plaintiff [2]. - The lawsuit follows the announcement of topline results from Altimmune's IMPACT Phase 2b trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint [3][4]. Group 3: Financial Impact - Following the announcement of the trial results, Altimmune's stock price dropped from $7.71 on June 25, 2025, to $3.61 on June 26, representing a decline of over 53% in one day [4].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2] Case Details - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [2] - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [2] Next Steps - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]